The pause in the phase 1 trial of SC-DARIC33 in acute myeloid leukemia has led to a decrease in 2Seventy Bio's stock price. This is because the trial's progress is crucial for the company's product pipeline and potential future revenues. Investors may be concerned about the delay and its implications on the company's prospects.